Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

null Natriuretic Peptides Studies Collaboration; Peter Willeit; Stephen Kaptoge; Paul Welsh; Adam Butterworth; Rajiv Chowdhury; Sarah Spackman; Lisa Pennells; Pei Gao; Stephen Burgess; Daniel Freitag; Michael Sweeting; Angela Wood; Nancy Cook; Suzanne Judd; Stella Trompet; Vijay Nambi; Michael Olsen; Brendan Everett; Frank Kee; Johan Ärnlöv; Veikko Salomaa; Daniel Levy; Jussi Kauhanen; Jari Laukkanen; Maryam Kavousi; Toshiharu Ninomiya; Juan-Pablo Casas; Lori Daniels; Lars Lind; Caroline Kistorp; Jens Rosenberg; Thomas Mueller; Speranza Rubattu; Demosthenes Panagiotakos; Oscar Franco; James de Lemos; Andreas Luchner; Jorge Kizer; Stefan Kiechl; Jukka Salonen; S Goya Wannamethee; Rudolf de Boer; Børge Nordestgaard; Jonas Andersson; Torben Jørgensen; Olle Melander; Christie Ballantyne; Christopher DeFilippi; Paul Ridker; Mary Cushman; Wayne Rosamond; Simon Thompson; Vilmundur Gudnason; Naveed Sattar; John Danesh; Emanuele Di Angelantonio

doi:10.1016/S2213-8587(16)30196-6

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

Natriuretic Peptides Studies Collaboration, Peter Willeit, Stephen Kaptoge, Paul Welsh, Adam Butterworth, Rajiv Chowdhury, Sarah Spackman, Lisa Pennells, Pei Gao, Stephen Burgess, Daniel Freitag, Michael Sweeting, Angela Wood, Nancy Cook, Suzanne Judd, Stella Trompet, Vijay Nambi, Michael Olsen, Brendan Everett, Frank KeeJohan Ärnlöv, Veikko Salomaa, Daniel Levy, Jussi Kauhanen, Jari Laukkanen, Maryam Kavousi, Toshiharu Ninomiya, Juan-Pablo Casas, Lori Daniels, Lars Lind, Caroline Kistorp, Jens Rosenberg, Thomas Mueller, Speranza Rubattu, Demosthenes Panagiotakos, Oscar Franco, James de Lemos, Andreas Luchner, Jorge Kizer, Stefan Kiechl, Jukka Salonen, S Goya Wannamethee, Rudolf de Boer, Børge Nordestgaard, Jonas Andersson, Torben Jørgensen, Olle Melander, Christie Ballantyne, Christopher DeFilippi, Paul Ridker, Mary Cushman, Wayne Rosamond, Simon Thompson, Vilmundur Gudnason, Naveed Sattar, John Danesh, Emanuele Di Angelantonio

Research output: Contribution to journal › Article › peer-review

179 Citations (Scopus)

321 Downloads (Pure)

Abstract

BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment.

METHODS: In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and collection of data from studies identified through a systematic search of the literature (PubMed, Scientific Citation Index Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk discrimination and reclassification across predicted 10 year risk categories (ie, <5%, 5% to <7·5%, and ≥7·5%), adding assessment of NT-proBNP concentration to that of conventional risk factors (ie, age, sex, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol concentrations). Primary outcomes were the combination of coronary heart disease and stroke, and the combination of coronary heart disease, stroke, and heart failure.

FINDINGS: We recorded 5500 coronary heart disease, 4002 stroke, and 2212 heart failure outcomes among 95 617 participants without a history of cardiovascular disease in 40 prospective studies. Risk ratios (for a comparison of the top third vs bottom third of NT-proBNP concentrations, adjusted for conventional risk factors) were 1·76 (95% CI 1·56-1·98) for the combination of coronary heart disease and stroke and 2·00 (1·77-2·26) for the combination of coronary heart disease, stroke, and heart failure. Addition of information about NT-proBNP concentration to a model containing conventional risk factors was associated with a C-index increase of 0·012 (0·010-0·014) and a net reclassification improvement of 0·027 (0·019-0·036) for the combination of coronary heart disease and stroke and a C-index increase of 0·019 (0·016-0·022) and a net reclassification improvement of 0·028 (0·019-0·038) for the combination of coronary heart disease, stroke, and heart failure.

INTERPRETATION: In people without baseline cardiovascular disease, NT-proBNP concentration assessment strongly predicted first-onset heart failure and augmented coronary heart disease and stroke prediction, suggesting that NT-proBNP concentration assessment could be used to integrate heart failure into cardiovascular disease primary prevention.

FUNDING: British Heart Foundation, Austrian Science Fund, UK Medical Research Council, National Institute for Health Research, European Research Council, and European Commission Framework Programme 7.

Original language	English
Pages (from-to)	840-849
Number of pages	10
Journal	The Lancet Diabetes & Endocrinology
Volume	4
Issue number	10
Early online date	03 Sept 2016
DOIs	https://doi.org/10.1016/S2213-8587(16)30196-6
Publication status	Published - Oct 2016

Keywords

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-8587(16)30196-6Licence: CC BY

Natriuretic peptides and integrated risk assessment for cardiovascular disease
Copyright 2016 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 470 KBLicence: CC BY

Cite this

Natriuretic Peptides Studies Collaboration, Willeit, P., Kaptoge, S., Welsh, P., Butterworth, A., Chowdhury, R., Spackman, S., Pennells, L., Gao, P., Burgess, S., Freitag, D., Sweeting, M., Wood, A., Cook, N., Judd, S., Trompet, S., Nambi, V., Olsen, M., Everett, B., ... Di Angelantonio, E. (2016). Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. The Lancet Diabetes & Endocrinology, 4(10), 840-849. https://doi.org/10.1016/S2213-8587(16)30196-6

@article{4d6f0bbfc7f84706b1b3c12efb18ecea,

title = "Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis",

abstract = "BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment.METHODS: In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and collection of data from studies identified through a systematic search of the literature (PubMed, Scientific Citation Index Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk discrimination and reclassification across predicted 10 year risk categories (ie, <5%, 5% to <7·5%, and ≥7·5%), adding assessment of NT-proBNP concentration to that of conventional risk factors (ie, age, sex, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol concentrations). Primary outcomes were the combination of coronary heart disease and stroke, and the combination of coronary heart disease, stroke, and heart failure.FINDINGS: We recorded 5500 coronary heart disease, 4002 stroke, and 2212 heart failure outcomes among 95 617 participants without a history of cardiovascular disease in 40 prospective studies. Risk ratios (for a comparison of the top third vs bottom third of NT-proBNP concentrations, adjusted for conventional risk factors) were 1·76 (95% CI 1·56-1·98) for the combination of coronary heart disease and stroke and 2·00 (1·77-2·26) for the combination of coronary heart disease, stroke, and heart failure. Addition of information about NT-proBNP concentration to a model containing conventional risk factors was associated with a C-index increase of 0·012 (0·010-0·014) and a net reclassification improvement of 0·027 (0·019-0·036) for the combination of coronary heart disease and stroke and a C-index increase of 0·019 (0·016-0·022) and a net reclassification improvement of 0·028 (0·019-0·038) for the combination of coronary heart disease, stroke, and heart failure.INTERPRETATION: In people without baseline cardiovascular disease, NT-proBNP concentration assessment strongly predicted first-onset heart failure and augmented coronary heart disease and stroke prediction, suggesting that NT-proBNP concentration assessment could be used to integrate heart failure into cardiovascular disease primary prevention.FUNDING: British Heart Foundation, Austrian Science Fund, UK Medical Research Council, National Institute for Health Research, European Research Council, and European Commission Framework Programme 7.",

keywords = "Journal Article",

author = "{Natriuretic Peptides Studies Collaboration} and Peter Willeit and Stephen Kaptoge and Paul Welsh and Adam Butterworth and Rajiv Chowdhury and Sarah Spackman and Lisa Pennells and Pei Gao and Stephen Burgess and Daniel Freitag and Michael Sweeting and Angela Wood and Nancy Cook and Suzanne Judd and Stella Trompet and Vijay Nambi and Michael Olsen and Brendan Everett and Frank Kee and Johan {\"A}rnl{\"o}v and Veikko Salomaa and Daniel Levy and Jussi Kauhanen and Jari Laukkanen and Maryam Kavousi and Toshiharu Ninomiya and Juan-Pablo Casas and Lori Daniels and Lars Lind and Caroline Kistorp and Jens Rosenberg and Thomas Mueller and Speranza Rubattu and Demosthenes Panagiotakos and Oscar Franco and {de Lemos}, James and Andreas Luchner and Jorge Kizer and Stefan Kiechl and Jukka Salonen and {Goya Wannamethee}, S and {de Boer}, Rudolf and B{\o}rge Nordestgaard and Jonas Andersson and Torben J{\o}rgensen and Olle Melander and Christie Ballantyne and Christopher DeFilippi and Paul Ridker and Mary Cushman and Wayne Rosamond and Simon Thompson and Vilmundur Gudnason and Naveed Sattar and John Danesh and {Di Angelantonio}, Emanuele",

year = "2016",

month = oct,

doi = "10.1016/S2213-8587(16)30196-6",

language = "English",

volume = "4",

pages = "840--849",

journal = "The Lancet Diabetes & Endocrinology",

issn = "2213-8587",

publisher = "UniCeSV - Universita degli Studi di Firenze",

number = "10",

}

Natriuretic Peptides Studies Collaboration, Willeit, P, Kaptoge, S, Welsh, P, Butterworth, A, Chowdhury, R, Spackman, S, Pennells, L, Gao, P, Burgess, S, Freitag, D, Sweeting, M, Wood, A, Cook, N, Judd, S, Trompet, S, Nambi, V, Olsen, M, Everett, B, Kee, F, Ärnlöv, J, Salomaa, V, Levy, D, Kauhanen, J, Laukkanen, J, Kavousi, M, Ninomiya, T, Casas, J-P, Daniels, L, Lind, L, Kistorp, C, Rosenberg, J, Mueller, T, Rubattu, S, Panagiotakos, D, Franco, O, de Lemos, J, Luchner, A, Kizer, J, Kiechl, S, Salonen, J, Goya Wannamethee, S, de Boer, R, Nordestgaard, B, Andersson, J, Jørgensen, T, Melander, O, Ballantyne, C, DeFilippi, C, Ridker, P, Cushman, M, Rosamond, W, Thompson, S, Gudnason, V, Sattar, N, Danesh, J & Di Angelantonio, E 2016, 'Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis', The Lancet Diabetes & Endocrinology, vol. 4, no. 10, pp. 840-849. https://doi.org/10.1016/S2213-8587(16)30196-6

TY - JOUR

T1 - Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

AU - Natriuretic Peptides Studies Collaboration, null

AU - Willeit, Peter

AU - Kaptoge, Stephen

AU - Welsh, Paul

AU - Butterworth, Adam

AU - Chowdhury, Rajiv

AU - Spackman, Sarah

AU - Pennells, Lisa

AU - Gao, Pei

AU - Burgess, Stephen

AU - Freitag, Daniel

AU - Sweeting, Michael

AU - Wood, Angela

AU - Cook, Nancy

AU - Judd, Suzanne

AU - Trompet, Stella

AU - Nambi, Vijay

AU - Olsen, Michael

AU - Everett, Brendan

AU - Kee, Frank

AU - Ärnlöv, Johan

AU - Salomaa, Veikko

AU - Levy, Daniel

AU - Kauhanen, Jussi

AU - Laukkanen, Jari

AU - Kavousi, Maryam

AU - Ninomiya, Toshiharu

AU - Casas, Juan-Pablo

AU - Daniels, Lori

AU - Lind, Lars

AU - Kistorp, Caroline

AU - Rosenberg, Jens

AU - Mueller, Thomas

AU - Rubattu, Speranza

AU - Panagiotakos, Demosthenes

AU - Franco, Oscar

AU - de Lemos, James

AU - Luchner, Andreas

AU - Kizer, Jorge

AU - Kiechl, Stefan

AU - Salonen, Jukka

AU - Goya Wannamethee, S

AU - de Boer, Rudolf

AU - Nordestgaard, Børge

AU - Andersson, Jonas

AU - Jørgensen, Torben

AU - Melander, Olle

AU - Ballantyne, Christie

AU - DeFilippi, Christopher

AU - Ridker, Paul

AU - Cushman, Mary

AU - Rosamond, Wayne

AU - Thompson, Simon

AU - Gudnason, Vilmundur

AU - Sattar, Naveed

AU - Danesh, John

AU - Di Angelantonio, Emanuele

PY - 2016/10

Y1 - 2016/10

N2 - BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment.METHODS: In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and collection of data from studies identified through a systematic search of the literature (PubMed, Scientific Citation Index Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk discrimination and reclassification across predicted 10 year risk categories (ie, <5%, 5% to <7·5%, and ≥7·5%), adding assessment of NT-proBNP concentration to that of conventional risk factors (ie, age, sex, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol concentrations). Primary outcomes were the combination of coronary heart disease and stroke, and the combination of coronary heart disease, stroke, and heart failure.FINDINGS: We recorded 5500 coronary heart disease, 4002 stroke, and 2212 heart failure outcomes among 95 617 participants without a history of cardiovascular disease in 40 prospective studies. Risk ratios (for a comparison of the top third vs bottom third of NT-proBNP concentrations, adjusted for conventional risk factors) were 1·76 (95% CI 1·56-1·98) for the combination of coronary heart disease and stroke and 2·00 (1·77-2·26) for the combination of coronary heart disease, stroke, and heart failure. Addition of information about NT-proBNP concentration to a model containing conventional risk factors was associated with a C-index increase of 0·012 (0·010-0·014) and a net reclassification improvement of 0·027 (0·019-0·036) for the combination of coronary heart disease and stroke and a C-index increase of 0·019 (0·016-0·022) and a net reclassification improvement of 0·028 (0·019-0·038) for the combination of coronary heart disease, stroke, and heart failure.INTERPRETATION: In people without baseline cardiovascular disease, NT-proBNP concentration assessment strongly predicted first-onset heart failure and augmented coronary heart disease and stroke prediction, suggesting that NT-proBNP concentration assessment could be used to integrate heart failure into cardiovascular disease primary prevention.FUNDING: British Heart Foundation, Austrian Science Fund, UK Medical Research Council, National Institute for Health Research, European Research Council, and European Commission Framework Programme 7.

AB - BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment.METHODS: In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and collection of data from studies identified through a systematic search of the literature (PubMed, Scientific Citation Index Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk discrimination and reclassification across predicted 10 year risk categories (ie, <5%, 5% to <7·5%, and ≥7·5%), adding assessment of NT-proBNP concentration to that of conventional risk factors (ie, age, sex, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol concentrations). Primary outcomes were the combination of coronary heart disease and stroke, and the combination of coronary heart disease, stroke, and heart failure.FINDINGS: We recorded 5500 coronary heart disease, 4002 stroke, and 2212 heart failure outcomes among 95 617 participants without a history of cardiovascular disease in 40 prospective studies. Risk ratios (for a comparison of the top third vs bottom third of NT-proBNP concentrations, adjusted for conventional risk factors) were 1·76 (95% CI 1·56-1·98) for the combination of coronary heart disease and stroke and 2·00 (1·77-2·26) for the combination of coronary heart disease, stroke, and heart failure. Addition of information about NT-proBNP concentration to a model containing conventional risk factors was associated with a C-index increase of 0·012 (0·010-0·014) and a net reclassification improvement of 0·027 (0·019-0·036) for the combination of coronary heart disease and stroke and a C-index increase of 0·019 (0·016-0·022) and a net reclassification improvement of 0·028 (0·019-0·038) for the combination of coronary heart disease, stroke, and heart failure.INTERPRETATION: In people without baseline cardiovascular disease, NT-proBNP concentration assessment strongly predicted first-onset heart failure and augmented coronary heart disease and stroke prediction, suggesting that NT-proBNP concentration assessment could be used to integrate heart failure into cardiovascular disease primary prevention.FUNDING: British Heart Foundation, Austrian Science Fund, UK Medical Research Council, National Institute for Health Research, European Research Council, and European Commission Framework Programme 7.

KW - Journal Article

U2 - 10.1016/S2213-8587(16)30196-6

DO - 10.1016/S2213-8587(16)30196-6

M3 - Article

C2 - 27599814

SN - 2213-8587

VL - 4

SP - 840

EP - 849

JO - The Lancet Diabetes & Endocrinology

JF - The Lancet Diabetes & Endocrinology

IS - 10

ER -

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this